Administrative Core

行政核心

基本信息

  • 批准号:
    10207345
  • 负责人:
  • 金额:
    $ 37.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-05 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

The major objectives of the Administrative Core are to institute an infrastructure that facilitates productive interactions among the U19 Program investigators of this grant application, “Defining regulators of immunity to acute infection using CRISPR screens” and implements our Pilot Project program. The Administrative Core will serve as a centralized, transparent organizational structure to provide administrative support that enables the Principal investigators and their personnel to focus on their experimental and scientific goals. Dr. Sharpe, Program Director of the overall U19 grant, will provide leadership and direction for operations of the Administrative Core, which will be based at Harvard Medical School. Dr. Haining, Co-Director of this U19 grant and Core A, will lead the Pilot Grant Program. The Administrative Core will be responsible for carrying out the following functions: a) Provide the infrastructure for overall management and co-ordination; b) Facilitate and promote interactions and communication between program investigators, scientific advisors and administrative personnel; c) Plan and coordinate annual External Scientific Advisory Group (ESAG) meetings; d) Organize and coordinate travel for ESAG members; e) Assist the Program Directors and Principal Investigators with oversight of scientific, fiscal, regulatory and compliance matters, and with preparation and review of yearly progress reports and financial reports; f) Implement a plan for data management/sharing among investigators; and g) Implement the Pilot Project Program. The Administrative Core will also resolve all conflicts that may arise. To achieve these goals, Core A has the following specific aims: Aim 1: To provide infrastructure for overall management and coordination. Core A will provide administrative support and coordination to promote communication and interactions among Project and Core investigators, including the scheduling of regular teleconferences/face-to-face meetings and annual meetings, preparing and submitting annual progress reports, providing fiscal oversight and ensuring institutional compliance with fiscal, regulatory and scientific issues, and conflict resolution. Aim 2: To maintain a web-based portal for data sharing via a secure Dropbox. Core A will host and manage a secure Dropbox portal for data sharing within the U19. This easy access to data will maximize transparency, encourage collaboration, and aid in monitoring project progress and how collaborators are utilizing core services. Aim 3: To implement the Pilot Project Program. Core A will develop an effective process to solicit review and award high caliber innovative Pilot Projects that use our in vivo CRISPR platform, and monitor their progress. We will encourage applications from early career investigators. Through these specific Aims, we will create an Administrative Core structured to implement processes/procedures to enable the success of this highly collaborative program.
行政核心的主要目标是建立一个便利的基础设施

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arlene H. Sharpe其他文献

The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
B7-CD28/CTLA-4 共刺激途径的复杂性。
Age-associated remodeling of T cell immunity and metabolism
T 细胞免疫和代谢的年龄相关重塑
  • DOI:
    10.1016/j.cmet.2022.11.005
  • 发表时间:
    2023-01-03
  • 期刊:
  • 影响因子:
    30.900
  • 作者:
    SeongJun Han;Peter Georgiev;Alison E. Ringel;Arlene H. Sharpe;Marcia C. Haigis
  • 通讯作者:
    Marcia C. Haigis
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8sup+/sup T cells
肿瘤细胞通过改变 CD8+T 细胞中的丙酮酸利用和琥珀酸盐信号来决定抗肿瘤免疫反应
  • DOI:
    10.1016/j.cmet.2022.06.008
  • 发表时间:
    2022-08-02
  • 期刊:
  • 影响因子:
    30.900
  • 作者:
    Ilaria Elia;Jared H. Rowe;Sheila Johnson;Shakchhi Joshi;Giulia Notarangelo;Kiran Kurmi;Sarah Weiss;Gordon J. Freeman;Arlene H. Sharpe;Marcia C. Haigis
  • 通讯作者:
    Marcia C. Haigis
The B7:CD28 family and friends: Unraveling coinhibitory interactions
B7:CD28 家族及朋友:解开共抑制相互作用
  • DOI:
    10.1016/j.immuni.2024.01.013
  • 发表时间:
    2024-02-13
  • 期刊:
  • 影响因子:
    26.300
  • 作者:
    Kelly P. Burke;Apoorvi Chaudhri;Gordon J. Freeman;Arlene H. Sharpe
  • 通讯作者:
    Arlene H. Sharpe
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
PD-L2 是 PD-1 的第二种配体,可抑制 T 细胞活化
  • DOI:
    10.1038/85330
  • 发表时间:
    2001-03-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary;Madhuri Borde;Irene Chernova;Yoshiko Iwai;Andrew J. Long;Julia A. Brown;Raquel Nunes;Edward A. Greenfield;Karen Bourque;Vassiliki A. Boussiotis;Laura L. Carter;Beatriz M. Carreno;Nelly Malenkovich;Hiroyuki Nishimura;Taku Okazaki;Tasuku Honjo;Arlene H. Sharpe;Gordon J. Freeman
  • 通讯作者:
    Gordon J. Freeman

Arlene H. Sharpe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arlene H. Sharpe', 18)}}的其他基金

Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    10210502
  • 财政年份:
    2020
  • 资助金额:
    $ 37.75万
  • 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
  • 批准号:
    10153453
  • 财政年份:
    2018
  • 资助金额:
    $ 37.75万
  • 项目类别:
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
项目2:治疗前、治疗期间以及耐药时的肿瘤和免疫微环境的测量和建模
  • 批准号:
    10343840
  • 财政年份:
    2018
  • 资助金额:
    $ 37.75万
  • 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
  • 批准号:
    9906872
  • 财政年份:
    2018
  • 资助金额:
    $ 37.75万
  • 项目类别:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
简化靶向治疗可提高抗 PD-1 抑制剂对黑色素瘤的疗效
  • 批准号:
    9576657
  • 财政年份:
    2018
  • 资助金额:
    $ 37.75万
  • 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    10207344
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
项目 1:通过 CRISPR 筛选发现 CD8 和 CD4 细胞命运和功能的调节因子
  • 批准号:
    10207349
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    9380804
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Core D: Mouse Perturbation Core
核心 D:鼠标扰动核心
  • 批准号:
    10207348
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:
Defining regulators of immunity to acute infection using CRISPR screens
使用 CRISPR 筛选定义急性感染免疫调节因子
  • 批准号:
    10266219
  • 财政年份:
    2017
  • 资助金额:
    $ 37.75万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 37.75万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 37.75万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了